The search for effective treatments for Alzheimer’s disease, a devastating neurodegenerative condition affecting an estimated 6.7 million Americans and millions more worldwide, has taken a potentially significant turn. Researchers have identified a previously unknown role for specialized brain cells, called Tanycytes, in clearing toxic proteins associated with the disease. This discovery, published in the journal Cell Press Blue, suggests a latest pathway for therapeutic intervention and fundamentally alters our understanding of how Alzheimer’s progresses.
Alzheimer’s disease is characterized by the accumulation of abnormal protein deposits in the brain, most notably amyloid plaques and tau tangles. While the exact causes remain complex and not fully understood, the buildup of tau protein is now widely considered a critical biomarker for the disease’s progression, leading to neuronal degeneration and cognitive decline. Currently, there is no cure for Alzheimer’s, and existing treatments offer only limited symptomatic relief. Globally, the impact is immense; the World Health Organization estimates nearly 55 million people live with dementia, with Alzheimer’s disease being the most common form.
The Unexpected Role of Tanycytes
For over two decades, a team led by Vincent Prévot of the French National Institute of Health and Medical Research (Inserm) and the University Hospital of Lille has been investigating the function of Tanycytes. These cells, located in a region of the brain called the circumventricular organs, act as a crucial interface between the brain and the body, regulating the exchange of information, and substances. Previous research by Prévot’s team demonstrated that Tanycytes play a role in transporting leptin, a hormone that regulates appetite, and disruptions in this transport can contribute to obesity and diabetes – both established risk factors for Alzheimer’s disease.
“We hypothesized that a similar transport dysfunction could contribute to brain aging and, neurodegenerative diseases like Alzheimer’s,” explains Prévot. The seven-year study began by investigating whether Tanycytes were involved in the transport of tau protein. Researchers injected fluorescently labeled tau protein into the cerebrospinal fluid (CSF) of mice and tracked its movement. The results were striking: Tanycytes actively captured the tau protein from the CSF and transported it to capillaries, effectively acting as a bridge between the fluid surrounding the brain and the bloodstream.
Blocking Transport Accelerates Disease Progression
To further confirm the role of Tanycytes, the researchers genetically blocked their transport function in mice. This disruption prevented the clearance of tau protein from the brain via the CSF. In parallel, they studied mouse models exhibiting early signs of Alzheimer’s and elevated tau levels. Blocking Tanycyte activity in these models led to a significantly accelerated progression of the disease, including the development of dementia-like symptoms. This provided strong evidence that Tanycytes are essential for removing tau protein and protecting against neurodegeneration.
Human Studies Confirm the Link
The team then sought to validate their findings in humans. They compared the ratio of tau protein in the blood and brain of healthy individuals and those with Alzheimer’s disease, assessing their ability to clear tau. “We found that the clearance capacity was significantly reduced in individuals with Alzheimer’s, suggesting an impairment in tau transport to the blood,” Prévot stated.
Perhaps the most compelling evidence came from examining the brains of deceased Alzheimer’s patients. Microscopic analysis revealed that the structures of Tanycytes were severely damaged and disrupted. “The bridges between the CSF and the blood were completely collapsed,” Prévot described. “There was no longer any communication, explaining why the removal of these toxic proteins was failing.” Importantly, this damage was specific to Alzheimer’s disease and not observed in the brains of patients with other forms of dementia.
A Paradigm Shift in Alzheimer’s Research
The identification of this mechanism represents a “fundamental shift in our understanding of Alzheimer’s disease,” according to Prévot. Philippe Amouyel, Director of the Alzheimer’s Foundation and Professor of Public Health at the University Hospital of Lille, agrees. “We knew about the elimination of abnormal proteins through the immune system and the glymphatic system, which is activated during sleep. Now, we have a third pathway involving Tanycytes. This is a new and interesting hypothesis.”
Prévot is optimistic that this discovery will pave the way for new therapeutic strategies. “Demonstrating that Tanycytes are compromised offers hope that One can target them directly. The priority is to prevent their deterioration, ideally before the process even begins.” He envisions a future where biomarkers can identify individuals at risk of Tanycyte dysfunction, allowing for lifestyle adjustments or preventative medication to strengthen these crucial cells.
However, Amouyel cautions that significant research remains. “First, we need to identify the risk factors that impact Tanycytes, and then develop interventions to stimulate their role in clearing tau protein.” The path to effective treatments is long, but this new understanding of Tanycytes offers a promising avenue for future exploration.
The next steps involve further investigation into the specific factors that cause Tanycyte dysfunction and the development of targeted therapies to protect and restore their function. Researchers are too exploring potential biomarkers that could identify individuals at risk of developing Alzheimer’s disease based on Tanycyte activity.
This research underscores the complexity of Alzheimer’s disease and the importance of continued investment in innovative research. If you or someone you know is affected by Alzheimer’s disease, resources and support are available through the Alzheimer’s Association and the National Institute on Aging.
This article is based on reporting originally published in Le Figaro, as part of the Leading European Newspaper Alliance (LENA). Translated from French by Bettina Schneider.
Related reading
